Fusion Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-94.9	-87.61	-81.05	-79.72	-16.19	-11.65	-6.26
Depreciation & Amortization	3.86	2.05	1.71	0.51	0.29	0.11	0.02
Share-Based Compensation	12.44	10.84	8.6	3.37	0.62	0.56	0.11
Other Operating Activities	-3.21	1.44	-5	44.69	1.59	1.12	0
Operating Cash Flow	-81.8	-73.28	-75.74	-29.77	-13.69	-9.87	-6.13
Capital Expenditures	-3.89	-2.14	-1.49	-1.12	-0.46	-1.12	-0.1
Change in Investments	-38.87	25.23	39.27	-209.33	0	0	0
Investing Cash Flow	-42.76	23.09	37.77	-210.45	-0.46	-1.12	-0.1
Share Issuance / Repurchase	146.04	6.04	0.62	197.68	0	0	0
Debt Issued / Paid	0	34.69	0	0	0	0	0
Other Financing Activities	-4.03	-	-0.28	67.83	52.19	18.37	27.17
Financing Cash Flow	142.01	40.73	0.35	265.51	52.19	18.37	27.17
Net Cash Flow	17.44	-9.46	-37.62	25.29	38.04	7.38	20.95
Free Cash Flow	-85.69	-75.42	-77.23	-30.89	-14.15	-10.99	-6.22
Free Cash Flow Margin	-4143.71%	-5162.08%	-5363.26%	-	-	-	-
Free Cash Flow Per Share	-1.31	-1.72	-1.81	-1.40	-7.38	-5.87	-3.32

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).